Protocol Ledger

NCT04839354 · Phase III · COMPLETED

Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial

Interventional Phase III clinical trial protocol NCT04839354 sponsored by Claudia R. Morris in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-21 Enrollment: 271 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04839354
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)271 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04839354
Protocol FieldVerified Registry Value
NCT IdentifierNCT04839354
Consolidated Lead SponsorClaudia R. Morris
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment271 participants (ACTUAL)
Registered Start Date2021-06-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI